FrancophonIA/ELRC3.0 huggingface dataset:
English: In this way atazanavir reduces the risk of developing illnesses linked to HIV infection.
Croatian: Na taj način atazanavir smanjuje rizik od razvoja bolesti povezanih s HIV infekcijom. kobicistat, pojačivač (farmakokinetički pojačivač) koji poboljšava učinke atazanavira.
English: Concentrations of atazanavir were not significantly affected.
Croatian: Nije bilo značajnog utjecaja na koncentracije atazanavira.
English: Tenofovir alafenamide 10 mg once daily (atazanavir 300 mg once daily with cobicistat 150 mg once daily)
Croatian: Tenofoviralafenamid 10 mg jedanput na dan (atazanavir 300 mg jedanput na dan s kobicistatom 150 mg jedanput na dan)
English: Omeprazole 20 mg once daily am (atazanavir 300 mg once daily with ritonavir 100 mg once daily pm, 12 hours after omeprazole)
Croatian: Omeprazol 20 mg jedanput na dan, ujutro (atazanavir 300 mg jedanput na dan i ritonavir 100 mg jedanput na dan, navečer, 12 sati nakon omeprazola)
English: EVOTAZ or any other medicinal product containing atazanavir should be discontinued if severe rash develops.
Croatian: Ako se razvije težak osip, potrebno je prekinuti primjenu lijeka EVOTAZ i bilo kojeg drugog lijeka koji sadrži atazanavir.
English: Medicinal products that may be affected by atazanavir/cobicistat Atazanavir is an inhibitor of CYP3A4 and UGT1A1.
Croatian: Atazanavir je inhibitor CYP3A4 i UGT1A1.
English: Atazanavir with ritonavirf (n = 348)
Croatian: ritonaviromf (n = 348)
English: Co-administration of bosentan with cobicistat may lead to decreased cobicistat plasma concentrations.
Croatian: Istodobna primjena bosentana i kobicistata može sniziti plazmatske koncentracije kobicistata.
English: Co-administration with EVOTAZ is expected to increase dolutegravir plasma concentrations.
Croatian: Očekuje se da će istodobna primjena s lijekom EVOTAZ povisiti plazmatske koncentracije dolutegravira.
English: Co-administration with EVOTAZ has the potential to increase warfarin plasma concentrations.
Croatian: Istodobna primjena s lijekom EVOTAZ može povisiti plazmatske koncentracije varfarina.
English: perphenazine, risperidone, thioridazine, midazolam (given by injection), buspirone, clorazepate, diazepam, estazolam, flurazepam and zolpidem (used to treat nevous system disorders) buprenorphine (used to treat opioid addiction and pain)
Croatian: metformin (primjenjuje se za liječenje šećerne bolesti tipa 2) varfarin, rivaroksaban i dabigatran (antikoagulansi, primjenjuju se za smanjenje zgrušavanja krvi) irinotekan, dasatinib, nilotinib, vinblastin i vinkristin (primjenjuju se za liječenje raka) trazodon (primjenjuje se za liječenje depresije) perfenazin, risperidon, tioridazin, midazolam (primijenjen injekcijom), buspiron, klorazepat, diazepam, estazolam, flurazepam i zolpidem (primjenjuju se za liječenje poremećaja živčanog sustava) buprenorfin (primjenjuje se za liječenje ovisnosti o opijatima i boli)
English: Atazanavir Cmax ↓9% (↓16% ↓1%) Atazanavir Cmin ↓19% (↓31%
Croatian: Atazanavir AUC ↓10% (↓18% ↓2%) Atazanavir Cmax ↓9% (↓16% ↓1%) Atazanavir Cmin ↓19% (↓31% ↓6%)
English: ANTIHISTAMINE AGENTS Astemizole
Croatian: Astemizol Terfenadin
English: BRISTOL-MYERS SQUIBB A.E.
Croatian: Bristol-Myers Squibb B.V.
English: Co-administration of EVOTAZ and cisapride is contraindicated (see section 4.3).
Croatian: Istodobna primjena lijeka EVOTAZ i cisaprida je kontraindicirana (vidjeti dio 4.3).
English: Co-administration of EVOTAZ and these ergot derivates is contraindicated (see section 4.3).
Croatian: Istodobna primjena lijeka EVOTAZ i navedenih derivata ergota je kontraindicirana (vidjeti dio 4.3).
English: Terfenadine
Croatian: Varfarin
English: For more information consult the cobicistat Summary of Product Characteristics.
Croatian: Za više informacija pročitajte Sažetak opisa svojstava lijeka za kobicistat.
English: Atazanavir Cmax ↑2% (↓4% ↑8%) Atazanavir Cmin ↑15% (↑2%
Croatian: Atazanavir AUC ↑7% (↓2% ↑17%) Atazanavir Cmax ↑2% (↓4% ↑8%) Atazanavir Cmin ↑15% (↑2% ↑29%)
English: Contraception requirements
Croatian: Primjena s kontracepcijom
English: Nevirapine 200 mg twice daily (atazanavir 300 mg once daily with ritonavir 100 mg once daily)
Croatian: Nevirapin 200 mg dvaput na dan (atazanavir 300 mg jedanput na dan i ritonavir 100 mg jedanput na dan)
English: Rifampicin 600 mg once daily (atazanavir 300 mg once daily with ritonavir 100 mg once daily)
Croatian: Rifampicin 600 mg jedanput na dan (atazanavir 300 mg jedanput na dan i ritonavir 100 mg jedanput na dan)
English: The mechanism of interaction is CYP3A inhibition by atazanavir and cobicistat.
Croatian: Mehanizam interakcije je inhibicija CYP3A koju uzrokuju atazanavir i kobicistat.
English: The mechanism of interaction is inhibition of CYP3A4 by cobicistat.
Croatian: Mehanizam interakcije je inhibicija CYP3A4 koju uzrokuje kobicistat.
English: Telaprevir AUC ↓20% (↓24% Telaprevir Cmax ↓21% (↓26% Telaprevir Cmin ↓15% (↓25% ↓2%) Atazanavir AUC ↑17% (↓3% Atazanavir Cmax ↓15% (↓27% Atazanavir Cmin ↑85% (↑40%
Croatian: Atazanavir AUC ↑17% (↓3% ↑43%) Atazanavir Cmax ↓15% (↓27% ↓2%) Atazanavir Cmin ↑85% (↑40% ↑144%)
English: No dose adjustment is required for telaprevir if co-administered with EVOTAZ.
Croatian: Nije potrebno prilagođavati dozu telaprevira pri istodobnoj primjeni s lijekom EVOTAZ.
English: ANTI-HCV AGENTS Grazoprevir 200 mg once daily (atazanavir 300 mg / ritonavir 100 mg once daily)
Croatian: Grazoprevir 200 mg jedanput na dan (atazanavir 300 mg/ritonavir 100 mg jedanput na dan)
English: Bristol-Myers Squibb B.V. Tel: + 31 (0)30 300 2222
Croatian: Bristol-Myers Squibb spol. s r.o. Tel: + 386 1 236 47 00
English: Concentrations of these calcium channel blockers may be increased when co-administered with EVOTAZ.
Croatian: Istodobna primjena s lijekom EVOTAZ može povisiti koncentracije navedenih blokatora kalcijevih kanala.
English: Cobicistat
Croatian: Tikagrelor
English: Co-administration of atorvastatin with EVOTAZ is not recommended.
Croatian: Ne preporučuje se istodobna primjena atorvastatina i lijeka EVOTAZ.
English: The mechanism of this interaction is CYP3A4 inhibition by atazanavir and cobicistat.
Croatian: Mehanizam ove interakcije je inhibicija CYP3A4 koju uzrokuju atazanavir i kobicistat.
English: Atazanavir Cmax ↓59% (↓77% Atazanavir Cmin ↓93% (↓95%
Croatian: Atazanavir AUC ↓74% (↓78% ↓68%) Atazanavir Cmax ↓59% (↓77% ↓49%) Atazanavir Cmin ↓93% (↓95% ↓90%)
English: The mechanism of interaction is inhibition of CYP3A4 by atazanavir and cobicistat.
Croatian: Mehanizam interakcije je inhibicija CYP3A4 koju uzrokuju atazanavir i kobicistat.
English: Concentrations of dabigatran may be affected upon co-administration with EVOTAZ.
Croatian: Istodobna primjena s lijekom EVOTAZ može utjecati na koncentracije dabigatrana.
English: Sofosbuvir AUC : ↑40% (↑25%
Croatian: Sofosbuvir AUC: ↑40% (↑25% ↑57%) Sofosbuvir Cmax:↑29% (↑9% ↑52%)
English: Recommendations concerning co-administration
Croatian: Preporuke kod istodobne primjene
English: Plasma concentrations of drospirenone are increased following administration of drospirenone/ethinyloestradiol with atazanavir/cobicistat.
Croatian: Istodobna primjena drospirenona/etinilestradiola s atazanavir/kobicistatom povisuju koncentracije drospirenona u plazmi.
English: Co-administration of EVOTAZ with products containing St. John's wort is contraindicated (see section 4.3).
Croatian: Istodobna primjena lijeka EVOTAZ i pripravaka koji sadrže gospinu travu je kontraindicirana (vidjeti dio 4.3).
English: Concentrations of these sedatives/hypnotics may be increased when co-administered with EVOTAZ.
Croatian: Istodobna primjena s lijekom EVOTAZ može povisiti koncentracije navedenih sedativa/hipnotika.
English: Cardiac disorders uncommon torsades de pointesa rare
Croatian: Poremećaji dišnog sustava, prsišta i sredoprsja manje često dispneja
English: Co-administration with bepridil is contraindicated (see section 4.3).
Croatian: Istodobna primjena s bepridilom je kontraindicirana (vidjeti dio 4.3).
English: Results are normally seen within 2 or 3 weeks of starting treatment.
Croatian: Rezultati su obično vidljivi nakon 2 ili 3 tjedna od početka liječenja.
English: After a week, the dose is increased every week by 0.5 mg a day, until the platelet count is below 600 million platelets per millilitre, and ideally between 150 and 400 million/ml (the level usually seen in healthy people).
Croatian: Nakon tjedan dana dnevna doza povećava se svaki tjedan za 0,5 mg sve dok broj trombocita ne padne ispod 600 milijuna po mililitru, a idealno između 150 i 400 milijuna/ml (razina uobičajena za zdrave osobe).
English: The full EPAR for Anagrelide Mylan can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za lijek Anagrelide Mylan nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This puts the patient at risk of developing blood clots or bleeding problems.
Croatian: To bolesnika izlaže riziku od stvaranja krvnih ugrušaka ili problema s krvarenjem.
English: Treatment should only be started by a doctor who has experience in treating essential thrombocythaemia.
Croatian: Liječenje smije započeti samo liječnik s iskustvom u liječenju esencijalne trombocitemije.
English: The recommended starting dose is one 0.5 mg capsule twice a day.
Croatian: Preporučena početna doza je jedna kapsula od 0,5 mg dvaput dnevno.
English: Anagrelide Mylan is also a ‘hybrid medicine' because it is available in an additional strength.
Croatian: Anagrelide Mylan također je „hibridni lijek” jer je dostupan u još jednoj dodatnoj jačini.
English: This reduces the platelet count, helping to improve symptoms in patients with the disease.
Croatian: Time se snižava broj trombocita, što pomaže smanjiti simptome u bolesnika s ovom bolešću.
English: This means that Anagrelide Mylan contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Xagrid.
Croatian: To znači da Anagrelide Mylan sadržava istu djelatnu tvar i djeluje na isti način kao i „referentni lijek” koji je već odobren u Europskoj uniji (EU) pod nazivom Xagrid.
English: As for every medicine, the company provided studies on the quality of Anagrelide Mylan.
Croatian: Kao i za svaki lijek, tvrtka je dostavila ispitivanja o kvaliteti lijeka Anagrelide Mylan.
English: Therefore, the Agency's view was that, as for Xagrid, the benefit outweighs the identified risk.
Croatian: Stoga je stav Agencije da, kao i za lijek Xagrid, korist nadmašuje utvrđeni rizik.
English: Anagrelide Mylan is used when the patient's current treatment does not work well enough or has unacceptable side effects, and when they are ‘at risk' because of their age (over 60 years), very high platelet counts or previous clotting problems.
Croatian: Anagrelide Mylan se primjenjuje kada postojeće bolesnikovo liječenje ne djeluje dovoljno dobro ili ima neprihvatljive nuspojave te kada su bolesnici izloženi riziku zbog svoje dobi (stariji od 60 godina), zbog vrlo velikog broja trombocita ili prethodnih problema sa zgrušavanjem.
English: Anagrelide Mylan is available as capsules (0.5 and 1 mg).
Croatian: Lijek Anagrelide Mylan dostupan je u kapsulama (od 0,5 i 1 mg).
English: This is a summary of the European public assessment report (EPAR) for Anagrelide Mylan.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) lijeka Anagrelide Mylan.
English: What measures are being taken to ensure the safe and effective use of Anagrelide Mylan?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Anagrelide Mylan?
English: Anagrelide Mylan anagrelide
Croatian: Anagrelide Mylan anagrelid
English: The European Medicines Agency concluded that, in accordance with EU requirements, Anagrelide Mylan has been shown to have comparable quality and to be bioequivalent to Xagrid.
Croatian: Europska agencija za lijekove zaključila je kako je, u skladu sa zahtjevima EU-a, za lijek Anagrelide Mylan dokazana usporediva kakvoća i bioekvivalentnost s lijekom Xagrid.
English: Studies on the benefits and risks of the active substance in the approved use have already been carried out with the reference medicine, Xagrid, and do not need to be repeated for Anagrelide Mylan.
Croatian: Ispitivanja koristi i rizika djelatne tvari u odobrenoj primjeni već su provedena za referentni lijek Xagrid, pa ih ne treba ponavljati za lijek Anagrelide Mylan.
English: Because Anagrelide Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Croatian: Budući da je Anagrelide Mylan generički lijek te da je bioekvivalentan referentnom lijeku, smatra se da su njegove koristi i rizici isti kao i oni referentnog lijeka.
English: Anagrelide Mylan is a medicine used to reduce the number of platelets (components that help the blood to clot) in patients with essential thrombocythaemia (a disease in which there are too many platelets circulating in the blood).
Croatian: Anagrelide Mylan je lijek koji se primjenjuje kako bi se smanjio broj trombocita (komponente koje pomažu u zgrušavanju krvi) u bolesnika s esencijalnom trombocitemijom (bolest pri kojoj krvotokom kruži prevelik broj trombocita). „Esencijalna” znači da ne postoji očit uzrok bolesti.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Anagrelide Mylan have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Anagrelide Mylan nalaze se u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: It is not intended to provide practical advice on how to use Anagrelide Mylan.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka Anagrelide Mylan.
English: Other information about Anagrelide Mylan
Croatian: Ostale informacije o lijeku Anagrelide Mylan
English: What are the benefits and risks of Anagrelide Mylan?
Croatian: Koje su koristi i rizici lijeka Anagrelide Mylan?
English: The maximum recommended dose of Anagrelide Mylan is 2.5 mg at a time.
Croatian: Najviša preporučena doza lijeka Anagrelide Mylan odjednom iznosi 2,5 mg.
English: For more information about treatment with Anagrelide Mylan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o liječenju lijekom Anagrelide Mylan pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svojem liječniku ili ljekarniku.
English: Essential thrombocythaemia is a disease in which the bone marrow produces too many platelets.
Croatian: Esencijalna trombocitemija je bolest pri kojoj koštana srž proizvodi previše trombocita.
English: The Agency recommended that Anagrelide Mylan be approved for use in the EU.
Croatian: Agencija je preporučila davanje odobrenja za stavljanje lijeka Anagrelide Mylan u promet u EU-u.
English: What is Anagrelide Mylan and what is it used for?
Croatian: Što je Anagrelide Mylan i za što se koristi?
English: The active substance in Anagrelide Mylan, anagrelide, blocks the development and growth of cells in the bone marrow called ‘megakaryocytes', which produce platelets.
Croatian: Djelatna tvar u lijeku Anagrelide Mylan, anagrelid, blokira razvoj i rast stanica u koštanoj srži koje proizvode trombocite, a nazivaju se „megakariociti”.
English: Anagrelide Mylan can only be obtained with a prescription.
Croatian: Anagrelide Mylan izdaje se samo na liječnički recept.
English: Anagrelide Mylan contains the active substance anagrelide and is a ‘generic medicine'.
Croatian: Anagrelide Mylan sadržava djelatnu tvar anagrelid te je „generički lijek”.
English: For practical information about using Anagrelide Mylan, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o primjeni lijeka Anagrelide Mylan bolesnici trebaju pročitati u uputi o lijeku, odnosno trebaju se obratiti svojem liječniku ili ljekarniku.
English: Why is Anagrelide Mylan approved?
Croatian: Zašto je lijek Anagrelide Mylan odobren?
English: How is Anagrelide Mylan used?
Croatian: Kako se Anagrelide Mylan koristi?
English: How has Anagrelide Mylan been studied?
Croatian: Kako je Anagrelide Mylan ispitivan?
English: This summary was last updated in 02-2018.
Croatian: Anagrelide Mylan EMA/8115/2018
English: How does Anagrelide Mylan work?
Croatian: Kako djeluje Anagrelide Mylan?
English: Adults (including the elderly)
Croatian: Odrasle osobe (uključujući starije)
English: Date of first authorisation: 25 July 2019
Croatian: Datum prvog odobrenja: 25. jula 2019. godine
English: Children < 5 years
Croatian: Djeca < 5 godina
English: Cufence with food and drink
Croatian: Cufence s hranom i pićem
English: Do not stop or change your treatment without speaking with your doctor even if you feel better.
Croatian: Nemojte zaustavljati ili mijenjati svoje liječenje bez razgovora sa svojim liječnikom čak i u slučaju da se osjećate bolje.
English: Do not take it with other drinks or food because they may reduce the medicine's effect.
Croatian: Nemojte uzimati lijek s drugim pićima ili hranom jer bi mogli smanjiti učinak lijeka.
English: However, a risk to the newborns/infants cannot be excluded.
Croatian: No nije moguće isključiti rizik za novorođenče/dojenče.
English: The safety and efficacy of Cufence in children aged 0 to 5 years have not yet been established.
Croatian: Sigurnost i djelotvornost lijeka Cufence u djece u dobi od 0 do 5 godina nisu još ustanovljene.
English: Capsules should be swallowed whole with water.
Croatian: Kapsule treba gutati cijele s vodom.
English: Exposure seems to be highly variable between subjects.
Croatian: Izloženost se čini vrlo varijabilnom između ispitanika.
English: Frequency of monitoring is recommended to be at least twice a year.
Croatian: Preporuča se da učestalost praćenja bude barem dva puta godišnje.
English: After first opening the bottle: 3 months.
Croatian: Nakon prvog otvaranja bočice: 3 mjeseca.
English: The doctor may need to increase or decrease your dose of Cufence.
Croatian: Vaš će liječnik možda trebati povećati ili smanjiti dozu lijeka Cufence.
English: You and your doctor should fully discuss the potential benefits of treatment whilst considering any possible risks that there may be.
Croatian: Vi i Vaš liječnik trebate u potpunosti raspraviti o mogućim koristima liječenja imajući na umu bilo kakve moguće rizike koji se mogu pojaviti.
English: Electrocardiography was also unaffected.
Croatian: Elektrokardiografska slika također je bila bez promjene.
English: Do not use if the capsules become sticky or wet.
Croatian: Lijek nemojte upotrebljavati ako kapsule postanu ljepljive ili vlažne.
English: What Cufence is and what it is used for
Croatian: Što je Cufence i za što se koristi
English: Your doctor will decide the correct dose for you.
Croatian: Vaš liječnik odredit će ispravnu dozu za Vas.
English: Store in a refrigerator (2ºC-8ºC).
Croatian: Čuvati u hladnjaku (2 ºC-8 ºC).
English: Other medicines and Cufence
Croatian: Drugi lijekovi i Cufence
English: At the start of treatment the dose varies between 2 and 5 capsules per day.
Croatian: Na početku liječenja doza varira između 2 i 5 kapsula dnevno.
English: If you forget to take a dose take your next dose at its usual scheduled time.
Croatian: Zaboravite li uzeti dozu, sljedeću dozu uzmite u uobičajeno vrijeme.
English: What you need to know before you take Cufence Do not take Cufence:
Croatian: Što morate znati prije nego počnete uzimati Cufence Nemojte uzimati Cufence:
English: It is possible that this effect may be more evident in patients with pre-existing neurological symptoms.
Croatian: Moguće je da će ovaj učinak biti izraženiji u bolesnika s već postojećim neurološkim simptomima.
English: Take this medicine with water only.
Croatian: Ovaj lijek treba uzimati samo s vodom.
English: There is insufficient clinical information available for Cufence to determine whether there exist differences in responses between the elderly and younger patients.
Croatian: Nema dovoljno dostupnih kliničkih podataka o lijeku Cufence da bi se utvrdilo postoje li razlike u odgovoru na liječenje između starijih i mlađih bolesnika.
English: If you are taking iron tablets or medicines that neutralise the acid in your stomach, leave at least 2 hours before or after you have taken Cufence because they may reduce Cufence's effect.
Croatian: Ako uzimate tablete sa željezom ili lijekove koji neutraliziraju kiselinu u želucu, uzmite ih barem 2 sata prije ili nakon što ste uzeli Cufence zato što oni mogu smanjiti učinak lijeka Cufence.
English: If you are allergic to trientine or any of the other ingredients of this medicine (listed in section 6).
Croatian: Ako ste alergični na trientin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
English: However it was not possible to determine if the reaction was due to trientine or to previous penicillamine treatment.
Croatian: Međutim, nije bilo moguće utvrditi je li reakcija posljedica liječenja trientinom ili prethodnog liječenja penicilaminom.
English: The study should be conducted according to an agreed protocol.
Croatian: Ispitivanje se mora provesti sukladno dogovorenom planu ispitivanja.
English: < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data).
Croatian: Učestalost se određuje na sljedeći način: vrlo često (≥ 1/10); često (≥ 1/100 do < 1/10); manje često (≥ 1/1000 do < 1/100); rijetko (≥ 1/10 000 do < 1/1000); vrlo rijetko (< 1/10 000); nepoznato (ne može se procijeniti na temelju dostupnih podataka).
English: What Cufence looks like and contents of the pack
Croatian: Kako Cufence izgleda i sadržaj pakiranja
English: Univar Solutions BV Schouwburgplein 30 3012 CL Rotterdam The Netherlands
Croatian: Univar Solutions BV Schouwburgplein 30 3012 CL Rotterdam Nizozemska
English: Some functional neurological abnormalities were also identified, particularly in severly affected animals, however no associated nerve damage was observed.
Croatian: Ustanovljen je i dio funkcionalnih neuroloških abnormalnosti, posebice u teže pogođenim životinjama, iako nije zamijećeno nikakvo povezano oštećenje živaca.
English: The dose is lower than for adults and depends on age and body weight.
Croatian: Doza je niža od doze za odrasle, a ovisi o dobi i tjelesnoj težini.
English: Swallow the capsules whole with a drink of water on an empty stomach, at least 1 hour before or 2 hours after food.
Croatian: Kapsule progutajte cijele uz čašu vode na prazan želudac, barem 1 sat prije ili 2 sata poslije jela.
English: Fertility It is unknown whether trientine has an effect on human fertility.
Croatian: Plodnost Nije poznato ima li trientin učinak na ljudsku plodnost.
English: The total daily dose can be divided into 2 to 4 smaller doses, as indicated by your doctor.
Croatian: Ukupnu dnevnu dozu moguće je podijeliti u 2 do 4 manje doze, u skladu s time kako propiše liječnik.
English: You must contact your doctor or another health care provider immediately.
Croatian: Smjesta se obratite svom liječniku ili drugom pružatelju zdravstvenih usluga.
English: The use of appropriate copper parameter target ranges is described in clinical practice guidelines related to Wilson's disease.
Croatian: Upotreba odgovarajućih ciljnih raspona parametara bakra opisana je u smjernicama kliničke prakse koje se odnose na Wilsonovu bolest.
English: Occasionally (frequency unknown; cannot be estimated from available data), treatment with this medicine can cause inflammation of the small intestine or colon.
Croatian: Povremeno (učestalost nepoznata; nije moguće procijeniti na temelju dostupnih podataka), liječenje ovim lijekom može izazvati upalu tankog ili debelog crijeva.
English: For specific precautions see section 4.4.
Croatian: Za određene mjere opreza vidjeti dio 4.4.
English: The recommended dose is 800-1,600 mg (4-8 capsules) daily in 2 to 4 divided doses.
Croatian: Preporučena doza iznosi 800 - 1600 mg (4 - 8 kapsula) dnevno podijeljena u 2 do 4 doze.